Efficacy and safety of blonanserin versus other antipsychotics: a review


  • Anant D. Patil Freelance consultant: Medical communication and training


Antipsychotic, Schizophrenia, Delirium, Efficacy, Safety


Although many atypical antipsychotics are available, there is a need of an atypical antipsychotic effective in all symptom domains of schizophrenia and well tolerated especially for side effects like extrapyramidal side effects, weight gain and blood prolactin elevation. Blonanserin is an atypical antipsychotic which blocks dopamine D2 and serotonin 5HT2A receptors. Its efficacy and safety has been studied in patients with schizophrenia and delirium. Blonanserin is found to be effective and well tolerated in both conditions. This article has reviewed efficacy and tolerability of blonanserin in these two psychiatry diseases.


Ghosh R, Bhatia MS, Bhattacharya SK. Blonanserin in management of Schizophrenia. Delhi Psychiatry Journal 2012; 15: 1: 406-411.

Kato K, Yamada K, Maehara M, Akama F, Kimoto K, Saito M et al. Blonanserin in the treatment of delirium. Psychiatry and Clinical Neurosciences 2011; 65: 389–391.

Furuse T, Hashimoto K. Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. Annals of General Psychiatry 2010;9:17.

Tenjin T, Miyamoto S, Miyake N, Ogino S, Kitajima R, Ojima K, et al. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia. Hum Psychopharmacol. 2012; Jan; 27; 1:90-100.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009, 23:615-625.

Yang J, Bahk WM, Cho HS, Jeon YW, Jon DI, Jung HY, et al. Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial. Clin Neuropharm 2010;33:169-175.

Azekawa T, Ohashi S, Itami A. Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatric Disease and Treatment 2011;7:691–695.

Takaki M, Okahisa, Y., Kodama, M., Mizuki, Y., Sakamoto, S., Ujike, H et al. Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia. Acta Neuropsychiatrica. 2012; 24: 380–383.

Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit. Care 2008; 12: 1–9.

Deeks ED, Keating GM. Blonanserin: A review of its use in the management of schizophrenia. CNS Drugs 2010; 24: 65–84.

Okugawa G. Effect of Blonanserin on Delirium in a Patient with Alzheimer Disease. The Open Psychiatry Journal, 2010;4:25-26.

Kato K, Akama F, Yamada K, Maehara M, Kimoto K, Kimoto K, et al. Blonanserin for the treatment of delirium patients at an emergency medical care center: An open-label study. Asian Journal of Psychiatry. April 2013;6(2):182-183.

13. Okugawa G. Effect of Blonanserin on Delirium in a Patient with Alzheimer Disease. The Open Psychiatry Journal 2010;4:25-26.

Takahashi S, Suzuki M, Uchiyama M. One-year follow-up study of psychotic patients treated with blonanserin: A case series. Asia-Pacific Psychiatry. 2012. doi: 10.1111/j.1758-5872.2012.00232.x.




How to Cite

Patil, A. D. (2017). Efficacy and safety of blonanserin versus other antipsychotics: a review. International Journal of Basic & Clinical Pharmacology, 2(6), 689–692. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1350



Review Articles